More on this later but this is a stunner. Merck hits 8-yr. low on worldwide withdrawal of Vioxx, its Cox-2 inhibitor. No word on its direct competitor Celebrex (from Pfizer) as yet, but there have been criticisms in the recent past that it’s ineffective in reducing stomach complaints compared to ibuprofen and NSAIDS as was originally claimed.